Back to the overview

‘BBio is on-track and is preparing exactly how EU has envisioned the EU Pandemic Preparedness program’ 

Delegation HERA visits Bilthoven Biologicals on Pandemic Preparedness Program

BILTHOVEN, May 23th 

At Bilthoven Biologicals (BBio) we were pleased to welcome the EU delegation with Mr. Muschel, Director of Health Emergency Preparedness (HERA).  

HERA, the agency overseeing EU Pandemic Preparedness, is part of the European Committee. Mr. Muschel was accompanied by Mrs. Klasja de Ridder, head of representation for the European Committee and HERA colleagues Niall Macaulay and Damiët Onderstal. Mrs. Frederique de Jong form the Ministry of Health, Welfare and Sport also joined the visit.  

CEO’s Jef de Clercq (PSP) and Jurgen Kwik (BBio) started off with a presentation on the current status of the Pandemic Preparedness program at BBio. Ad van den Biggelaar (COO BBio) and Jorrit van Hoorn (Director Corporate Development) lead the delegation on a tour on the premisses, where the work packages were discussed on various locations by the work package leads: 

  • Supply Chain by Michel Staal 
  • Quality Control by Lineke Pelleboer 
  • Drug Substance by Claudia Tietz 
  • Drug Product by Olaf Daviena 
  • Rapid Tech Transfer by Pascal de Jong 

Mr. Muschel and the EU delegation were well informed and detailed discussions took place. In the words of Mr Muschel: “The EU delegation is very impressed about the progress, facilities and the pandemic preparedness program at BBio. BBio is on-track and is preparing exactly how EU has envisioned the EU Pandemic Preparedness program.”   

Strengthened by these words and the well-recognized valuable support of the Serum Institute of India team, BBio will continue towards the timeline as per end of June 2024 when we will submit our 12 months implementation report to the EU.